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Interleukin-33 (IL-33) is associated with the development of Th2 responses. This study examined the potential role of IL-33 in
the pathogenic process of chronic hepatitis C (CHC) in Chinese patients. The levels of serum IL-33 and sST2 in 154 patients
with CHC, 24 with spontaneously resolved HCV (SR-HCV) infection and 20 healthy controls (HC), were analyzed by ELISA.
The concentrations of serum IL-2, IFN-γ,T N F - α, IL-4, IL-6, and IL-10, HCV loads, ALT, AST, and HCV-Ab were measured. We
found that the levels of serum IL-33 in CHC patients were signiﬁcantly higher than those of SR-HCV and HC but decreased after
treatmentwithinterferonfor12weeks.Moreimportantly,thelevelsofserumIL-33werecorrelatedwiththeconcentrationsofALT
and AST in CHC patients. The levels of serum sST2, as a decoy receptor of IL-33, were signiﬁcantly higher in CHC and SR-CHC
patients than those in HC, and there was no correlation between the levels of serum sST2 and IL-33. The concentrations of serum
IFN-γ and IL-6 in CHC patients were signiﬁcantly lower than those of SR-HCV. These data suggest that IL-33 may be a pathogenic
factor contributing to CHC-related liver injury.
1.Introduction
Hepatitis C virus (HCV) is one of the major causes of
chronic liver disease in the world [1]. More importantly,
many of those patients with chronic hepatitis C eventually
develop cirrhosis and hepatocellular carcinoma [2]. Fol-
lowing infection with HCV, only about 15% of patients
can clear the virus, while 60–80% of patients develop
persistent chronic infection [3, 4]. Previous studies have
revealed that the persistence of viral infection and chronic
inﬂammation are dependent on the interaction among the
virus, hepatocyte, and the host immune system [4, 5]. The
viral infection and related hepatocyte injuries are known to
suppress the immune system [6, 7]. Although experimental
evidence suggests that antigen-speciﬁc Th1 immunity and
proinﬂammatory cytokines play an important role in the
HCV-related liver injury and clearance of viruses [8–10], the
pathogenesis of chronic HCV infection has not been fully
understood.
Interleukin-33 (IL-33) is one of the newly described
membersintheIL-1familyandcanbeproducedbyepithelial
tissues and vascular endothelial cells [11]. IL-33 binds
to its heterodimer receptors composed of IL-1 receptor-
related protein ST2 and IL-1 receptor accessory protein
(IL-1RaP) and can activate the MyD88 and NF-κB-related
signal pathway [11, 12]. ST2 has transmembrane form of
ST2 (ST2 or ST2L) and soluble form of ST2 (sST2). ST2 is
expressed on Th2 and mast cells and functions as a mediator
of IL-33 bioactivities, while sST2 acts as a decoy receptor
for IL-33. Biologically, IL-33 induces Th2 cell diﬀerentiation
and activates mast cells, leading to Th2 cytokine production
and Th2 response as well as pulmonary and mucosal Th2
inﬂammation [11]. Furthermore, IL-33 can antagonize the
LPS-induced mortality in a model of septic shock [12],
and the levels of serum IL-33 were elevated in SLE and
RA patients [13]. Recently, IL-33 has been found to be an
important factor of the pathogenesis of HIV infection and
dengue virus infection [14, 15]. However, little is known on2 Mediators of Inﬂammation
whether IL-33 could participate in the pathogenic process of
HCV infection.
In the current study, we examined the concentrations
of serum IL-33 and sST2 in patients with chronic hepatitis
C (CHC), individuals with spontaneously resolved HCV
infection (SR-HCV), and healthy controls (HC) to evaluate
the potential role of IL-33/ST2 axis in the pathogenic process
of CHC. Furthermore, we determined the concentrations of
serum IL-33 before and after antivirus therapies in patients
with CHC. We found that IL-33 response appeared to be an
importantfactorofthepathogenesisofCHC,associatedwith
the severity of liver injury in CHC patients. We discuss the
implications of our ﬁndings.
2.MaterialsandMethods
2.1. Patients. A total of 154 patients with CHC, 24 cases with
SR-HCV,wererecruitedsequentiallyattheoutpatientservice
of First Hospital. Another 20 gender-, age- and ethnic-
matched HC were recruited, and they had no historical liver
diseases and no evidence of HBV, HCV, and HDV infection.
Individuals with positive anti-HCV antibodies and serum
HCV RNA for at least six months were diagnosed with
CHC [16]. Individuals with SR-HCV were deﬁned as those
subjects who had prior HCV RNA detection (HCV-Ab+)b u t
lacked HCV RNA detection for 12 weeks after enrollment in
the absence of treatment [17]. Genotyping of HCV showed
that 22 CHC patients had genotype 2a, 45 had genotype
1b, and 14 had unclassiﬁed genotype. Individuals with
historical and current hepatitis B, D virus or HIV infection,
autoimmune hepatitis, or metabolic liver disease, who had
received immunosuppressive therapy or antiviral therapy
during the past 12 months before entry, were excluded. All
patientsdenieddruguseorexposuretoobvioushepatotoxin.
Their demographic and clinical characteristics are shown in
Table 1.
Fifty patients with CHC were treated subcutaneously
with 500 million units of a short-acting interferon (SINO-
GEN, Jinan, China) every other day for 12 weeks. The con-
centrations of serum IL-33, sST2, HCV-RNA, ALT, and AST
were measured before and after treatment. Individuals with
100-fold reduced serum virus load were deﬁned as drug-
responsive patients; otherwise, individuals were deﬁned as
drug-nonresponsive patients. Written informed consent was
obtained from individual participants, and the study was
approved by the First Hospital Ethical Committee of Jilin
University.
Peripheral blood samples were obtained from individual
subjects, and their sera were prepared and then stored at
−80◦C till needed. The levels of serum IL-33 were measured
at the entry of individual participants, before and after
treatment of patients with CHC, and the concentrations
of serum IFN-γ,T N F - α, IL-2, IL-4, IL-10, and IL-6 in
individual CHC patients were also determined.
2.2. Measurement of IL-33 and sST2 by ELISA. The concen-
trations of serum IL-33 and sST2 in individual patients and
healthy controls were determined by ELISA using human
Table 1: Demographic characteristics and clinical features of par-
ticipants.
Parameters HCV SR-HCV Healthy
controls
Number 154 24 20
Age (years) 47
(28–65)
52
(31–57)
47
(42–54)
Sex (M/F) 110/44 15/9 14/6
Viraemia
(log10 copies/mL)
6.0
(1.3–7.6) NA NA
ALT (U/L) 25
(5–420)∗
21
(7–87)
14
(5–26)
AST (U/L) 31
(4–226)∗
17
(6–57)
12
(8–32)
Anti-HCV Positive Positive Negative
Normal values (NA): ALT ≤ 50IU/L; AST ≤ 40IU/L; HCV RNA ≤
300copies/mL; ∗P<0.05 versus SR-HCV or HC. Data were expressed as
median and range.
IL-33 and sST2 ELISA kits, according to the manufactur-
ers’ instruction (Roche Diagnostics, Lewes, UK). Brieﬂy,
individual sera at 1:4 dilutions were subjected to ELISA
analysis, and the concentrations of serum IL-33 and sST2 in
individualsampleswerecalculated,accordingtothestandard
curve established using the recombinant IL-33 and sST2
provided. The detection limitation of the IL-33 and sST2
ELISA kit was 0–16ng/L and 1.6ng/L, respectively.
2.3. Cytometric Bead Array of Serum Cytokines. The concen-
trations of serum cytokine levels (IFN-γ,T N F - α, IL-2, IL-4,
IL-10, and IL-6) were determined by cytometric bead array
(CBA) [18], according to the manufacturer’s protocol (BD
Biosciences,SanJoes,USA)withminormodiﬁcation.Brieﬂy,
25μL of individual sera was used in duplicate for analysis,
as described previously [19]. The concentrations of serum
cytokines were quantiﬁed using the CellQuestPro and CBA
software (Becton Dickinson) on a FACSCalibur cytometry
(BD Biosciences).
2.4. Serologic Analysis of Hepatitis. The concentrations of
serum antibodies against HCV were detected by ELISA II
(Abbott Laboratories, Abbott Park, USA) [20]. The levels
of serum ALT and AST were detected using a Biochem-
istry Automatic Analyzer (Roche Diagnostics, Branchburg,
USA). The amounts of serum HCV RNA were measured
by quantitative PCR assay using a luciferase quantization
detection kit, following the protocols (Roche Amplicor,
Basel, Switzerland). The detection limit of viral RNA was
300copies/mL.
2.5. Statistical Analysis. The data are expressed as median
and range unless speciﬁed. The diﬀerences between the
groups were analyzed by Wilcoxon-rank sum test and chi-
square test using the SPSS 14.0 software. The relationship
between variables was evaluated using the Spearman rankMediators of Inﬂammation 3
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Figure 1: The levels of serum IL-33. The concentrations of serum IL-33 in individual CHC patients, those with SR-HCV and HC, and the
levels of serum ALT and AST were determined by ELISA and automatic enzymatic assays, respectively. The potential association of the levels
of serum IL-33, ALT, and AST was analyzed using the Spearman rank correlation test. Data are expressed as the mean values of individual
participantsfromtwoseparateexperiments.Thehorizontallinesindicatethemedianvalues ofdiﬀerentgroups.(a)Thebasallevels ofserum
IL-33; (b) the levels of serum IL-33 in those with diﬀerent levels of serum ALT; (c) the levels of serum IL-33 in those with diﬀerent levels of
serum AST; (d) the correlation between the levels of serum IL-33 and ALT; (e) the correlation between the levels of serum IL-33 and AST.
HC: healthy controls; CHC: patients with CHC; SR-HCV: individual with spontaneously resolved HCV patients (SR-HCV).
correlation test. A two-sided P value <0.05 was considered
statistically signiﬁcant.
3. Results
To determine the potential role of IL-33 in the pathogenic
process of CHC, a total 154 patients with CHC, 24 with
SR-HCV, and 20 with HC were sequentially recruited. As
expected, there was no signiﬁcant diﬀerence in the distri-
bution of age and gender among these groups of subjects,
but the concentrations of serum ALT and AST in patients
with CHC were signiﬁcantly higher than those in the HC
and those with SR-HCV (Table 1). While high levels of virus
RNA were detected in CHC patients, there was no detectable
viremia in both HC and SR-HCV. In addition, the anti-HCV
antibody was detected in CHC patients and individuals with
SR-HCV, but not in HC.
Analysis of serum cytokines indicated that there was
no signiﬁcant diﬀerence in the concentrations of serum IL-
33 between individuals with SR-HCV and HC, while the
concentrations of serum IL-33 in patients with CHC were
signiﬁcantly higher than those in individuals with SR-HCV
a n dH C( P<0.001, Figure 1(a)).
Furthermore, stratiﬁcation of patients with CHC
revealed that the concentrations of serum IL-33 in CHC
patients with abnormal levels of serum ALT (>50units/L)
or AST (>40units/L) were signiﬁcantly higher than those
in CHC patients with normal levels of ALT (<50units/L) or
AST (<40units/L), respectively (P<0.001, P<0.001, resp.,
Figures 1(b) and 1(c)). The concentrations of serum IL-33
in CHC patients were correlated positively with the levels
of serum ALT and AST (r = 0.388, P<0.001; r = 0.400,
P<0.001, resp., Figures 1(d) and 1(e)). Apparently, IL-33
is a pathogenic factor, associated with the damage of the4 Mediators of Inﬂammation
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Figure 2: The levels of serum sST2. The concentrations of serum
sST2 in individual CHC patients, those with SR-HCV and HC,
were determined by ELISA. Data are expressed as the mean values
of individual participants from two separate experiments. The
horizontal lines indicate the median values of diﬀerent groups.
liver in CHC patients. Further analysis revealed that the
levels of serum sST2 were signiﬁcantly higher in CHC and
SR-CHC patients than that in HC (P = 0.004, P = 0.041,
resp., Figure 2), but there was no signiﬁcant correlation
between the levels of serum IL-33 and sST2 in those subjects
(r =− 0.050, P = 0.678). Moreover, the concentrations
of serum IFN-γ and IL-6, but not TNF-α, IL-2, IL-10,
and IL-4, in patients with CHC, were signiﬁcantly lower
than those in individuals with SR-HCV (Figures 3(a) and
3(b)). Following treatment of CHC patients with IFN for
12 weeks, 45 out of 50 CHC patients displayed dramatically
reduced levels of serum HCV virions. Notably, treatment
with IFN remarkably reduced IL-33 responses in those
patients because the levels of serum IL-33 in patients with
CHC after treatment with IFN were signiﬁcantly lower than
those before treatment. (P = 0.002, Figure 4(a)). However,
treatment with IFN for 12 weeks did not change signiﬁcantly
in the levels of serum sST2 in CHC patients (P = 0.641,
Figure 4(b)).
4. Discussions
IL-33 is a multifunctional cytokine involved in various
disease conditions [21–23]. IL-33, through the receptor
complex composed of ST2 and IL-1RaP, can activate the
MAP kinase and NF-κB signal pathways and promote Th2
response and cytokine production [11]. Indeed, intranasal
administration of IL-33 triggered an immediate allergic
response in the airway, and endogenous IL-33 contributes to
airway inﬂammation [24]. A recent study revealed that the
levels of serum IL-33 were elevated in SLE and RA patients
and correlated with the levels of serum ESR and CRP, two
inﬂammation markers, indicating that IL-33 may participate
in the acute-phase response of SLE [13]. In addition, IL-33
can protect against septic shock by enhancing neutrophils
inﬁltration at the site of inﬂammation [12]. Other studies
suggest that IL-33 participates in the pathogenic process
of acute hepatitis induced by Con-A [25, 26], and IL-
33 overexpression is associated with the development of
HBV/HCV-related liver ﬁbrosis [27]. To investigate the role
of IL-33 in the pathogenic process of CHC, we determined
the levels of serum IL-33 and sST2 in 154 CHC patients. We
found that the levels of serum IL-33 in CHC patients were
signiﬁcantly higher than in those with SR-HCV and HC.
Furthermore, the levels of serum IL-33 in CHC patients with
abnormal concentrations of ALT or AST were signiﬁcantly
higher than in those with normal levels of ALT and AST in
this population. In addition, treatment with IFN to inhibit
the replication of HCV dramatically decreased the levels
of serum IL-33 in CHC patients. More importantly, the
concentrations of serum IL-33 were correlated positively
with the levels of serum ALT and AST in CHC patients.
Given that abnormal levels of ALT and AST are indicative
of abnormal liver function and injuries, our data suggest that
IL-33 may be a pathogenic factor of the pathogenic process
of CHC in Chinese patients. Therefore, if the levels of serum
IL-33 are also correlated with pathogenic degrees of the liver
in CHC patients, the levels of serum IL-33 may be used as a
new biomarker for the diagnosis of liver damages in CHC
patients. Furthermore, we found that the levels of serum
sST2 were signiﬁcantly higher in CHC and SR-CHC patients
than those in HC, but were not correlated with the levels
of IL-33 in patients. Treatment with IFN for 12 weeks did
not signiﬁcantly change the levels of serum sST2. A previous
study has shown that the levels of serum sST2 in patients
with acute liver failure are higher than in those with chronic
liver failure and healthy controls [28]. It is possible that high
levels of serum sST2 are an early biomarker of liver injury,
while high levels of serum IL-33 may be associated with the
development and progression of liver ﬁbrosis and damage
[27]. We are interested in further examining the mechanisms
underlyingtheactionofIL-33/sST2axisinHCV-relatedliver
injury.
We found that the levels of serum IFN-γ and IL-6 in
CHCpatientsweresigniﬁcantlylowerthanthoseinSR-HCV,
supporting the notion that proinﬂammatory cytokines, such
as IFN-γ and IL-6, are not only important factors for the
clearance of infected HCV, but also for liver injury [29–31].
The lower levels of IFN-γ and IL-6 in CHC patients were
unlikely to have come from the antagonization of IL-33-
induced Th2 responses in those patients, because we failed
to detect signiﬁcant diﬀerence in the levels of serum IL-4
and IL-10 between those CHC patients and SR-HCV and
HC. Given that IL-6 is a critical factor of the functional
development of Th17 cells [32] and that IFN-γ is an eﬀector
of Th1 response [33], the lower levels of serum IFN-γ
and IL-6 in those CHC patients indicated continual viral
replication and pathogenic progression. Although IL-33 has
been shown to promote IFN-γ production by invariant NKT
and NK cells [34], IL-33 may, through an unknown pathway,Mediators of Inﬂammation 5
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Figure 3: The basal levels of serum IFN-γ and IL-6. The concentrations of serum IFN-γ and IL-6 in individual participants were determined
by CBA. Data are expressed as the mean values of individual samples from two separate experiments. The horizontal lines show the median.
(a) The levels of serum IFN-γ; (b) the levels of serum IL-6.
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Figure 4: The changes in the levels of serum IL-33 and sST2 in CHC patients with IFN treatment. Data are expressed as the mean values of
individual participants from two separate experiments. The horizontal lines show the median. (a) The changes in the levels of serum IL-33
in CHC patients with IFN treatment; (b) the changes in the levels of serum sST2 in CHC patients with IFN treatment.
downregulate the functional development of HCV-related
Th1 response and inhibit IFN-γ production. However, the
precise mechanisms remain to be further investigated.
In conclusion, our data indicate, for the ﬁrst time, that
the concentrations of serum IL-33 are signiﬁcantly higher in
those with SR-HCV and HC and are signiﬁcantly correlated
with the levels of serum ALT and AST, suggesting that
IL-33 may be a pathogenic factor of HCV-related liver
injury in CHC patients. We recognized that the current
study has limitations, including no source for IL-33 and
no histopathological examination of liver tissues. Although
more detailed studies are necessary to determine the role and6 Mediators of Inﬂammation
mechanisms of IL-33 in regulating the pathogenic process
of CHC, our novel ﬁndings may provide new insights into
understanding the pathogenesis of CHC.
Acknowledgments
This study was supported by Grants from the National
Natural Science Foundation of China (no. 30972610), Jilin
Province Science and Technology Agency (nos. 200705128
and 20110716), the Chinese Medical Science and Technology
Projects of Jilin Province (no. 08sys-086), the Health Depart-
ment ResearchProjects in Jilin Province (no. 2009Z054), and
the Cutting-edge Science and Interdisciplinary Innovation
Projects of Jilin University. The authors thank Medjaden
Bioscience Limited for assisting in the preparation of this
paper. J. Wang and P. Zhao contributed equally to this study.
References
[ 1 ]A .A l b e r t i ,L .C h e m e l l o ,a n dL .B e n v e g n` u, “Natural history of
hepatitis C,” Journal of Hepatology, vol. 31, no. 1, pp. 17–24,
1999.
[2] S. D. Crockett and E. B. Keeﬀe, “Natural history and treatment
of hepatitis B virus and hepatitis C virus coinfection,” Annals
of Clinical Microbiology and Antimicrobials, vol. 4, article 13,
12 pages, 2005.
[3] B. Rehermann and M. Nascimbeni, “Immunology of hepatitis
B virus and hepatitis C virus infection,” Nature Reviews
Immunology, vol. 5, no. 3, pp. 215–229, 2005.
[4] B. Rehermann, “Interaction between the hepatitis C virus and
the immune system,” Seminars in Liver Disease,v o l .2 0 ,n o .2 ,
pp. 127–141, 2000.
[5] P. Ciborowski and H. E. Gendelman, “Human immunodeﬁ-
ciency virus-mononuclear phagocyte interactions: emerging
avenuesofbiomarkerdiscovery,modesofviralpersistenceand
disease pathogenesis,” Current HIV Research, vol. 4, no. 3, pp.
279–291, 2006.
[6] F. Martini, C. Agrati, G. D’Oﬃzi, and F. Poccia, “HLA-E up-
regulation induced by HIV infection may directly contribute
to CD94-mediated impairment of NK cells,” International
Journal of Immunopathology and Pharmacology, vol. 18, no. 2,
pp. 269–276, 2005.
[7] M. I. Gonzalez, N. Rubinstein, J. M. Ilarregui, M. A. Toscano,
N. A. Sanjuan, and G. A. Rabinovich, “Regulated expression
of galectin-1 after in vitro productive infection with herpes
simplex virus type 1: implications for T cell apoptosis,”
International Journal of Immunopathology and Pharmacology,
vol. 18, no. 4, pp. 615–623, 2005.
[ 8 ]E .S c h v o e r e r ,M .C .N a v a s ,C .T h u m a n ne ta l . ,“ P r o d u c t i o no f
interleukin-18 and interleukin-12 in patients suﬀering from
chronic hepatitis C virus infection before antiviral therapy,”
Journal of Medical Virology, vol. 70, no. 4, pp. 588–593, 2003.
[9] F. Katia, U. Claudio, D. Margherita et al., “Modulation of
serum interleukin-18 concentrations and hepatitis B virus
DNAlevelsduringinterferontherapyinpatientswithhepatitis
be-antigen-positive chronic hepatitis B,” Annals of Clinical &
Laboratory Science, vol. 36, pp. 144–150, 2006.
[10] H. Wright, P. Alex, T. Nguyen et al., “Multiplex cytokine
proﬁling of initial therapeutic response in patients with
chronic hepatitis C virus infection,” Digestive Diseases and
Sciences, vol. 50, no. 10, pp. 1793–1803, 2005.
[11] J. Schmitz, A. Owyang, E. Oldham et al., “IL-33, an
interleukin-1-like cytokine that signals via the IL-1 receptor-
related protein ST2 and induces T helper type 2-associated
cytokines,” Immunity, vol. 23, no. 5, pp. 479–484, 2005.
[12] J. C. Alves-Filho, F. Sˆ onego, F. O. Souto et al., “Interleukin-33
attenuates sepsis by enhancing neutrophil inﬂux to the site of
infection,” Nature Medicine, vol. 16, no. 6, pp. 708–712, 2010.
[13] Z. X. Yang, Y. Liang, W. Q. Xi, C. Li, and R. Zhong,
“Association of increased serum IL-33 levels with clinical and
laboratory characteristics of systemic lupus erythematosus in
Chinese population,” Clinical and Experimental Medicine, vol.
11, pp. 75–80, 2011.
[14] A. Becerra, R. V. Warke, N. de Bosch, A. L. Rothman, and I.
Bosch, “Elevated levels of soluble ST2 protein in dengue virus
infected patients,” Cytokine, vol. 41, no. 2, pp. 114–120, 2008.
[15] T. Miyagaki, M. Sugaya, H. Yokobayashi et al., “High levels of
solubleST2andlowlevelsofIL-33inseraofpatientswithHIV
infection,” Journal of Investigative Dermatology, vol. 131, no. 3,
pp. 794–796, 2011.
[16] M. Sherman, S. Shafran, K. Burak et al., “Management of
chronic hepatitis B: consensus guidelines,” Canadian Journal
of Gastroenterology, vol. 21, pp. 25C–34C, 2007.
[17] M. Sarasin-Filipowicz, “Interferon therapy of hepatitis C:
molecular insights into success and failure,” Swiss Medical
Weekly, vol. 140, no. 1-2, pp. 3–11, 2010.
[18] E. Morgan, R. Varro, H. Sepulveda et al., “Cytometric bead
array: a multiplexed assay platform with applications in
various areas of biology,” Clinical Immunology, vol. 110, no.
3, pp. 252–266, 2004.
[19] A. T´ arnok, J. Hambsch, R. Chen, and R. Varro, “Cytometric
bead array to measure six cytokines in twenty-ﬁve microliters
of serum,” Clinical Chemistry, vol. 49, no. 6, pp. 1000–1002,
2003.
[20] A. Li, M. Yuan, Z. Huang, J. Fan et al., “Novel double-antigen
sandwich immunoassay for human hepatitis B core antibody,”
Clinical and Vaccine Immunology, vol. 17, no. 3, pp. 464–469,
2010.
[21] H. E. Barksby, S. R. Lea, P. M. Preshaw, and J. J. Taylor,
“The expanding family of interleukin-1 cytokines and their
role in destructive inﬂammatory disorders,” Clinical and
Experimental Immunology, vol. 149, no. 2, pp. 217–225, 2007.
[22] M. Y. Mok, F. P. Huang, D. Xu et al., “Serum levels of IL-33
and soluble ST2 and their association with disease activity in
systemic lupus erythematosus,” Rheumatology, vol. 49, no. 3,
Article ID kep402, pp. 520–527, 2009.
[23] F. Y.Liew, N. I.Pitman, andI.B.McInnes,“Disease-associated
functions of IL-33: the new kid in the IL-1 family,” Nature
Reviews Immunology, vol. 10, no. 2, pp. 103–110, 2010.
[24] J. Louten, A. L. Rankin, and Y. Li, “Endogenous IL-33
enhances Th2 cytokine production and T-cell responses
duringallergic airway inﬂammation,” International Immunol-
ogy, vol. 23, no. 5, pp. 307–315, 2011.
[25] V. Volarevic, M. Mitrovic, and M. Milovanovic, “Protective
role of IL-33/ST2 axis in Con A-induced hepatitis,” Journal of
Hepatology, vol. 56, no. 1, pp. 26–33, 2012.
[26] M. I. Arshad, M. Rauch, A. L’Helgoualc’h et al., “NKT cells
are required to induce high IL-33 expression in hepatocytes
during Con A-induced acute hepatitis,” European Journal of
Immunology, vol. 41, no. 8, pp. 2341–2348, 2011.
[27] P. Marvie, M. Lisbonne, A. L’Helgoualc’h et al., “Interleukin-
33 overexpression is associated with liver ﬁbrosis in mice and
humans,” Journal of Cellular and Molecular Medicine, vol. 14,
no. 6, pp. 1726–1739, 2010.Mediators of Inﬂammation 7
[28] G. A. Roth, M. Zimmermann, B. A. Lubsczyk et al., “Up-
regulation of interleukin 33 and soluble ST2 serum levels in
liver failure,” J o u r n a lo fS u r g i c a lR e s e a r c h , vol. 163, no. 2, pp.
e79–e83, 2010.
[29] D. H. Li, A. Kumanogoh, T. M. Cao, J. R. Parnes, and J. M.
Cullen, “Woodchuck interleukin-6 gene: structure, character-
ization, and biologic activity,” Gene, vol. 342, no. 1, pp. 157–
164, 2004.
[30] M. Ghoneum and M. Matsuura, “Augmentation of macro-
phage phagocytosis by modiﬁed arabinoxylan rice bran
(MGN-3/Biobran),”InternationalJournalofImmunopathology
and Pharmacology, vol. 17, no. 3, pp. 283–292, 2004.
[31] M. Frese, V. Schw¨ arzle, K. Barth et al., “Interferon-γ inhibits
replication of subgenomic and genomic hepatitis C virus
RNAs,” Hepatology, vol. 35, no. 3, pp. 694–703, 2002.
[32] H. Y. Chun, J. W. Chung, H. A. Kim et al., “Cytokine IL-6 and
IL-10 as biomarkers in systemic lupus erythematosus,” Journal
of Clinical Immunology, vol. 27, no. 5, pp. 461–466, 2007.
[33] Y. Jiang, Z. Ma, G. Xin et al., “Th1 and Th2 immune response
in chronic hepatitis B patients during a long-term treatment
with adefovir dipivoxil,” Mediators of Inﬂammation, vol. 2010,
2010.
[34] E. Bourgeois, L. P. Van, M. Samson et al., “The pro-Th2
cytokine IL-33 directly interacts with invariant NKT and
NK cells to induce IFN-γ production,” European Journal of
Immunology, vol. 39, no. 4, pp. 1046–1055, 2009.